Please login to the form below

Not currently logged in
Email:
Password:

etanercept

This page shows the latest etanercept news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

Sun Pharma passes milestone with novel psoriasis drug approval

inhibitor Enbrel (etanercept), a widely-used biologic for the skin condition.

Latest news

More from news
Approximately 8 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets.

  • Deal Watch October 2016 Deal Watch October 2016

    For example Samsung Bioepis also based in South Korea, signed a deal with Merck &Co in 2013 for a range of biosimilars including infliximab, trastuzumab and etanercept (Amgen's Enbrel with ... The FDA accepted the Biologics Licence Application for

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    drugs Humira (adalimumab) and Enbrel (etanercept) - last year's first and third best selling drugs respectively - are also in the biosimilar firing line.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    255. Coherus Biosciences / Baxter International. Licence. Etanercept biosimilar for rhematoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon.

  • Brand leaders in RA will lose market share, predict rheumatologists

    market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics